Pharmacodynamics of meropenem in the treatment of severe pneumonia in children

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200061207

Enrollment

Unknown

Registered

2022-06-15

Start date

2022-06-01

Completion date

Unknown

Last updated

2023-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Severe pneumonia in children

Interventions

Group 1 :20 mg/kg, q8h, with 0.5h infusion

Group 2:20 mg/kg, q8h, with 4h infusion

Eligibility

Sex/Gender

All

Age

0.2 Years to 15 Years

Inclusion criteria

Inclusion criteria: 1. Children from 3 months to 15 years old; 2. The pathogen or clinical diagnosis of severe pneumonia; 3. Treatment with meropenem; 4. Meropenem treatment time is longer than 48 hours; 5. Normal renal function (consider serum creatinine, blood urea nitrogen, and creatinine clearance); 6. Written ICF signed by parent or legal guardian. In addition, children aged 8 to 15 need to sign the International Child Health Convention in person.

Exclusion criteria

Exclusion criteria: 1. Meropenem allergy; 2. Receive other experimental drugs; 3. The predicted survival period is shorter than the duration of treatment; 4. There are other factors that clinicians think are not suitable for inclusion in this study.

Design outcomes

Primary

Measure	Time frame
blood drug concentration;	—

Secondary

Measure	Time frame
liver function;renal function;white blood cells;blood neutrophils;C-reactive protein;	—

Countries

China

Contacts

Public ContactAdong Shen

Beijing Children's Hospital, Capital Medical University

shenad16@hotmail.com+86 13370115087

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 11, 2026